What are the recommended evaluation and management guidelines for an adult patient presenting with a breast mass?

Evaluation and Management of Breast Masses

Initial Imaging Strategy: Age-Based Algorithm

For any palpable breast mass, imaging must be performed before surgical referral or biopsy, as tissue sampling creates hematoma and architectural distortion that obscure subsequent image interpretation. 1

Women ≥40 Years

• Begin with bilateral diagnostic mammography (place a radio-opaque marker over the palpable area) followed immediately by targeted breast ultrasound of the abnormal region. 1
• This combined approach provides a negative predictive value >97% when both studies are benign. 1
• Mammography detects 86–91% of breast cancers in this age group, while ultrasound identifies 93–100% of cancers that are occult on mammography. 1

Women 30–39 Years

• Either diagnostic mammography or targeted ultrasound may be chosen first, based on clinical suspicion. 1
• Ultrasound sensitivity approaches 95% in this age group, exceeding mammography sensitivity of approximately 61%. 1
• If ultrasound shows suspicious features (BI-RADS 4 or 5), obtain bilateral diagnostic mammography before proceeding to biopsy. 1

Women <30 Years

• Proceed directly to targeted breast ultrasound as the initial study. 1
• Reserve mammography only for cases where ultrasound shows suspicious findings or clinical examination is highly concerning. 1
• Breast cancer incidence is <1% in this population, making routine mammography unjustifiable as a first step. 1

Pregnant or Lactating Women (All Ages)

• Initiate evaluation with targeted breast ultrasound regardless of age, as increased breast density limits mammographic utility. 1
• Mammography is not contraindicated and should be performed when malignancy is suspected, demonstrating 90–100% sensitivity for detecting malignancy. 1

---

Management Based on BI-RADS Classification

BI-RADS 1–2 (Negative or Benign)

• When imaging shows a definitive benign correlate (simple cyst, lipoma, benign lymph node, hamartoma) that corresponds to the palpable finding, return to routine screening only—no further imaging or biopsy is needed. 1
• If a simple cyst is aspirated and blood-free fluid is obtained with complete resolution of the mass, monitor for recurrence; if the mass recurs, proceed to ultrasound-guided biopsy. 2

BI-RADS 3 (Probably Benign)

• Schedule short-interval follow-up with physical examination ± imaging every 6–12 months for 1–2 years. 2, 1
• If the lesion remains stable or resolves, return to routine screening. 2
• If the lesion increases in size or changes characteristics, proceed immediately to biopsy. 2
• Exception for high-risk patients: Proceed directly to core-needle biopsy rather than surveillance in patients with BRCA mutations, strong family history, awaiting organ transplant, known synchronous cancers, attempting conception, or severe anxiety. 1

BI-RADS 4–5 (Suspicious or Highly Suggestive of Malignancy)

• Perform image-guided core-needle biopsy immediately—core biopsy is superior to fine-needle aspiration for sensitivity, specificity, accurate histologic grading, and enables hormone-receptor testing. 1
• Verify concordance between pathology results, imaging findings, and clinical examination; discordant results require additional tissue sampling or surgical excision. 2, 1

Negative Imaging but Clinically Suspicious Examination

• A highly suspicious physical examination must prompt a palpation-guided biopsy even if imaging is negative, because clinical findings should not be overridden by imaging alone. 1
• Physical examination alone shows only 73% agreement among experienced examiners on the need for biopsy among proven malignancies. 1

---

Post-Biopsy Management

Benign Concordant Pathology

• Conduct physical examinations every 6–12 months for 1–2 years; if stable, return to routine screening. 2

High-Risk or Indeterminate Pathology

• Surgical excision is mandatory for atypical hyperplasia, LCIS, papillary lesions, radial scars, mucin-producing lesions, or potential phyllodes tumors due to significant risk of underestimating malignancy. 2, 1
• Select patients with atypical hyperplasia or LCIS may be suitable for monitoring in lieu of surgical excision. 2
• If atypical hyperplasia or LCIS is confirmed, initiate routine breast screening along with risk-reduction therapy. 2

Malignant Pathology

• Refer immediately for definitive treatment according to breast cancer management guidelines. 2

---

Special Clinical Scenarios

Nipple Discharge Without Palpable Mass

• Evaluate discharge characteristics first: bilateral milky discharge suggests pregnancy or endocrine origin; consider medications (psychoactive drugs, antihypertensives, opiates, oral contraceptives, estrogen). 2
• The most worrisome discharge is persistent, spontaneous, unilateral, from a single duct, and clear/colorless, serous, sanguinous, or serosanguineous. 2
• Guaiac test and cytology of nipple discharge are not recommended, as negative results should not alter management. 2
• For nonspontaneous, multiple-duct discharge in women <40 years, observe and educate the patient to stop breast compression; in women ≥40 years, perform screening mammography. 2

Skin Changes or Inflammatory Signs

• If skin changes include erythema, peau d'orange, or nipple alterations, consider inflammatory breast cancer or Paget's disease; obtain bilateral diagnostic mammography ± ultrasound first, then perform punch biopsy of skin or nipple regardless of imaging outcome. 1
• Do not postpone evaluation with antibiotics unless infection is strongly suspected. 1

Fibroadenoma Management

• Surgical excision is indicated for fibroadenomas >2 cm, suspected phyllodes tumor (rapid growth, large size), or patient request/anxiety. 3
• Core needle biopsy is preferred over fine-needle aspiration for better sensitivity, specificity, and histological grading. 3
• If pathology confirms benign fibroadenoma, return to routine screening; if atypical features are found, follow risk-reduction guidelines. 3

---

Critical Pitfalls to Avoid

• Never perform biopsy before completing all recommended imaging, as biopsy-related changes (hematoma, architectural distortion) obscure subsequent image interpretation. 1
• Never delay imaging evaluation for women ≥30 years; observation without imaging is unacceptable. 1
• Do not order MRI, PET, or molecular breast imaging as initial evaluation of a palpable mass—these modalities have no role in routine workup. 1
• Do not rely on diagnostic mammography alone; ultrasound must be performed even when mammography appears reassuring. 1
• Never assume benignity based solely on clinical features such as cyclic changes, soft texture, or mobility. 4
• Physical examination correctly identifies only 58% of palpable cysts, making imaging essential. 4